

Sabine Hoves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4767075/publications.pdf>

Version: 2024-02-01

31
papers

4,990
citations

257450

24
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

9177
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitory effect of tumor cell-derived lactic acid on human T cells. <i>Blood</i> , 2007, 109, 3812-3819.	1.4	1,361
2	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	16.8	1,033
3	Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. <i>Blood</i> , 2006, 107, 2013-2021.	1.4	541
4	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	229
5	Suppression of microRNA activity amplifies IFN- γ -induced macrophage activation and promotes anti-tumour immunity. <i>Nature Cell Biology</i> , 2016, 18, 790-802.	10.3	214
6	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 859-876.	8.5	150
7	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. <i>Cancer Cell</i> , 2016, 30, 377-390.	16.8	141
8	Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 3249-3261.	3.7	130
9	Therapeutic Efficacy of Bifunctional siRNA Combining TGF- β 1 Silencing with RIG-I Activation in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 1709-1720.	0.9	130
10	Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 1280-1297.	7.3	126
11	Effects of social stress on blood leukocyte distribution: the role of β - and α -adrenergic mechanisms. <i>Journal of Neuroimmunology</i> , 2004, 156, 153-162.	2.3	110
12	CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. <i>Current Opinion in Pharmacology</i> , 2015, 23, 45-51.	3.5	107
13	ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells. <i>Journal of Immunology</i> , 2011, 187, 55-63.	0.8	105
14	The battlefield of perforin/granzyme cell death pathways. <i>Journal of Leukocyte Biology</i> , 2010, 87, 237-243.	3.3	67
15	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	7.1	66
16	Monocyte-Derived Human Macrophages Mediate Anergy in Allogeneic T Cells and Induce Regulatory T Cells. <i>Journal of Immunology</i> , 2006, 177, 2691-2698.	0.8	54
17	Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. <i>Immunology</i> , 2010, 131, 257-267.	4.4	44
18	Presentation of tumour antigens by dendritic cells and challenges faced. <i>Current Opinion in Immunology</i> , 2010, 22, 137-144.	5.5	42

#	ARTICLE	IF	CITATIONS
19	Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses. <i>Journal of Immunology</i> , 2018, 201, 2273-2286.	0.8	38
20	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. , 2020, 8, e001153.		37
21	Mature But Not Immature Fas Ligand (CD95L)-Transduced Human Monocyte-Derived Dendritic Cells Are Protected from Fas-Mediated Apoptosis and Can Be Used as Killer APC. <i>Journal of Immunology</i> , 2003, 170, 5406-5413.	0.8	36
22	A drug development perspective on targeting tumor-associated myeloid cells. <i>FEBS Journal</i> , 2018, 285, 763-776.	4.7	31
23	Targeting tumor-associated macrophages in cancer therapy and understanding their complexity. <i>Oncolimmunology</i> , 2014, 3, e955356.	4.6	27
24	Elimination of activated but not resting primary human CD4 and CD8 T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. <i>Immunobiology</i> , 2004, 208, 463-475.	1.9	25
25	A Critical Role for Granzymes in Antigen Cross-Presentation through Regulating Phagocytosis of Killed Tumor Cells. <i>Journal of Immunology</i> , 2011, 187, 1166-1175.	0.8	24
26	Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	24
27	The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis. <i>Methods</i> , 2003, 31, 127-134.	3.8	15
28	Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. <i>PLoS ONE</i> , 2019, 14, e0219517.	2.5	11
29	A novel role for granzymes in anti-tumor immunity. <i>Oncolimmunology</i> , 2012, 1, 219-221.	4.6	10
30	A new flow cytometric assay for the simultaneous analysis of antigen-specific elimination of T cells in heterogenous T cell populations. <i>Journal of Immunological Methods</i> , 2009, 344, 98-108.	1.4	9
31	Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells. <i>Immunology</i> , 2011, 133, 115-122.	4.4	5